

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 March 2024 (07.03.2024)



(10) International Publication Number
WO 2024/049926 A1

(51) International Patent Classification:

A61K 31/496 (2006.01) A61P 35/00 (2006.01)
A61K 31/506 (2006.01) A61P 35/04 (2006.01)
A61K 31/519 (2006.01)

(21) International Application Number:

PCT/US2023/031574

(22) International Filing Date:

30 August 2023 (30.08.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/402,651	31 August 2022 (31.08.2022)	US
63/443,892	07 February 2023 (07.02.2023)	US
63/454,422	24 March 2023 (24.03.2023)	US
63/454,485	24 March 2023 (24.03.2023)	US
63/508,503	15 June 2023 (15.06.2023)	US

(71) Applicants: **ARVINAS OPERATIONS, INC.**, [US/US]; 5 Science Park, 395 Winchester Ave, New Haven, Connecticut 06511 (US). **PFIZER INC.**, [US/US]; 66 Hudson Boulevard East, New York, New York 10001-2192 (US).

(72) Inventors: **PECK, Ronald**; 29 Applewood Drive, Cheshire, Connecticut 06410 (US). **GOUGH, Sheryl Maxine**; 1202 Avalon Way, Stratford, Connecticut 06614 (US). **FLANAGAN, John J.**; 71 High Meadow Road, Guilford, Connecticut 06437 (US). **ANDERSON, Sibyl**; 68 Bradhurst Avenue, New York, New York 10039 (US). **TAYLOR, Ian Charles Anthony**; 149 Country Way, Madison, Connecticut 06443 (US). **SMITH, Julia Perkins**; c/o Pfizer Inc., 66 Hudson Boulevard East, New York, New York 10001-2192 (US). **TAN, Weiwei**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US).

(74) Agent: **PAXTON, Thomas J.** et al.; Cooley LLP, 1299 Pennsylvania Ave. NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: DOSAGE REGIMENS OF ESTROGEN RECEPTOR DEGRADERS



(57) Abstract: Disclosed herein are methods for treating cancer comprising administering to a subject a daily dose of Compound A, or a pharmaceutically acceptable salt thereof, in combination with a CDK4/6 inhibitor.

WO 2024/049926 A1